Related Experiment Videos
Thrombin inhibitors as anticoagulant agents
Current Opinion in Hematology
|September 1, 1999
Summary
New antithrombotic agents like hirudin analogues offer advantages over heparin. While effective short-term for acute cardiac events, long-term benefits of these specific thrombin inhibitors are not sustained.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hematology
Background:
- Antithrombotic therapy is crucial for managing thromboembolic disorders.
- Heparin and low-molecular-weight heparin are standard treatments but have limitations.
- Novel antithrombotic agents, including direct thrombin inhibitors, are emerging.
Purpose of the Study:
- To review recent clinical trial data on specific antithrombin agents.
- To evaluate their efficacy in acute cardiac ischemic syndromes.
- To assess their role in venous thromboembolism and heparin-induced thrombocytopenia.
Main Methods:
- Review of well-designed randomized clinical trials.
- Analysis of data from studies on hirudin analogues and synthetic antithrombin agents.
- Evaluation of short-term and long-term treatment outcomes.
Main Results:
- Specific thrombin inhibitors significantly reduce composite cardiac endpoints in acute ischemic syndromes.
- Advantages over heparin and low-molecular-weight heparin, including oral bioavailability, are noted.
- Short-term treatment benefits are not sustained long-term.
Conclusions:
- Specific antithrombin agents show promise in acute cardiac ischemic syndromes.
- These agents are valuable in preventing and treating venous thromboembolism.
- They offer a therapeutic option for managing heparin-induced thrombocytopenia.